Pharmaceuticals, Biotechnology and Life Sciences
Lenzilumab™ clinical development program for COVID-19 advances from IND to completion of Phase 3 enrollment in fewer than 12 months
Company completes two equity offerings in 2020, including uplisting to Nasdaq, to fund manufacturing scale-up and c…
Reports positive Phase 1 study results for Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder
Awarded subcontract license by U.S. government agency to formulate biologic countermeasures to be used by the U.S. military
Announces feasibil…
Reports positive Phase 1 study results for Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder
Awarded subcontract license by U.S. government agency to formulate biologic countermeasures to be used by the U.S. military
Announces feasibil…
Lenzilumab™ clinical development program for COVID-19 advances from IND to completion of Phase 3 enrollment in fewer than 12 months
Company completes two equity offerings in 2020, including uplisting to Nasdaq, to fund manufacturing scale-up and c…
– FOTIVDA is the First Therapy Approved for Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies –
– AVEO Plans to Make FOTIVDA Available to Patients in the U.S. by March 31, 2021 –
…
– FOTIVDA is the First Therapy Approved for Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies –
– AVEO Plans to Make FOTIVDA Available to Patients in the U.S. by March 31, 2021 –
…
– FOTIVDA is the First Therapy Approved for Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies –
– AVEO Plans to Make FOTIVDA Available to Patients in the U.S. by March 31, 2021 –
…
PHILADELPHIA–(BUSINESS WIRE)–Chimeron Bio, an RNA company pioneering a novel class of mRNA-based vaccines and therapeutics, is pleased to announce the appointment of Dr. Juan José Daboub and Dr. Wilmot James to its Accessible Medicines Advisory Board…
TG4050: first patients treated in two clinical trials of the novel individualized immunotherapy based on the myvac® technology – First data expected in 4Q 2021
TG4001: expanded randomized Phase II trial to start in HPV-positive anogenital cancers…
– Enrollment of the first patient is expected in Q2 2021
– Trial will focus on patients without liver metastases, based on encouraging data in Phase Ib/II study
– Trial targets indications where clinical outcomes can be improved versus standard therap…